{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:56:43Z","timestamp":1792612603393,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13318-024-00924-1","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T16:24:34Z","timestamp":1731083074000},"page":"23-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation"],"prefix":"10.1007","volume":"50","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Lukacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","volume":"12","author":"U Petriti","year":"2023","unstructured":"Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review and meta-analysis. Syst Rev. 2023;12:5. https:\/\/doi.org\/10.1186\/s13643-023-02169-6.","journal-title":"Syst Rev"},{"issue":"1","key":"924_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, Skinner SA, Merritt J, Lieberman DN, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180(1):55\u201367. https:\/\/doi.org\/10.1002\/ajmg.b.32707.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"924_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2020-000731","volume":"4","author":"C Fu","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, et al. Multisystem comorbidities in classic Rett syndrome: a scoping review. BMJ Paediatr Open. 2020;4: e000731. https:\/\/doi.org\/10.1136\/bmjpo-2020-000731.","journal-title":"BMJ Paediatr Open."},{"key":"924_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12883-023-03181-y","volume":"23","author":"D May","year":"2023","unstructured":"May D, Kponee-Shovein K, Mahendran M, Downes N, Sheng K, Lefebvre P, et al. Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study. BMC Neurol. 2023;23:141. https:\/\/doi.org\/10.1186\/s12883-023-03181-y.","journal-title":"BMC Neurol"},{"issue":"8","key":"924_CR5","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1007\/s12325-024-02926-6","volume":"41","author":"M Darwish","year":"2024","unstructured":"Darwish M, Obianom ON, Youakim JM, Darling I, Lukacova V, Bradley H. Effect of hepatic impairment on trofinetide exposures using an in silico physiologically based pharmacokinetic model. Adv Ther. 2024;41(8):3328\u201341. https:\/\/doi.org\/10.1007\/s12325-024-02926-6.","journal-title":"Adv Ther"},{"issue":"1","key":"924_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","volume":"44","author":"M Darwish","year":"2024","unstructured":"Darwish M, Nunez R, Youakim JM, Robertson P Jr. Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects. Clin Drug Investig. 2024;44(1):21\u201333. https:\/\/doi.org\/10.1007\/s40261-023-01322-2.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"924_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clinthera.2023.12.007","volume":"46","author":"M Darwish","year":"2024","unstructured":"Darwish M, Youakim JM, Darling I, Lukacova V, Owen JS, Bradley H. A physiologically based pharmacokinetic modeling approach to assess the potential for drug interactions between trofinetide and CYP3A4-metabolized drugs. Clin Ther. 2024;46(3):194\u2013200. https:\/\/doi.org\/10.1016\/j.clinthera.2023.12.007.","journal-title":"Clin Ther"},{"issue":"16","key":"924_CR8","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/wnl.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92(16):e1912\u201325. https:\/\/doi.org\/10.1212\/wnl.0000000000007316.","journal-title":"Neurology"},{"key":"924_CR9","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"109s","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;109s:S98\u2013s107. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.032.","journal-title":"Eur J Pharm Sci"},{"key":"924_CR10","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing: guidance for industry. 2020. https:\/\/www.fda.gov\/media\/78573\/download. Accessed 29 Feb 2024."},{"key":"924_CR11","unstructured":"Simulations Plus, Inc. GastroPlus\u00aeUser\u2019s Manual [computer program]. Version 9.8.2. Lancaster, CA: 2021."},{"issue":"4","key":"924_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004.","journal-title":"Ann Intern Med"},{"issue":"4","key":"924_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766\u201372. https:\/\/doi.org\/10.1373\/clinchem.2006.077180.","journal-title":"Clin Chem"},{"issue":"1","key":"924_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"924_CR15","unstructured":"Simulations Plus, Inc. GastroPlus\u00ae [computer program]. Version 9.8.2. Lancaster, CA: 2021."},{"key":"924_CR16","unstructured":"R Foundation for Statistical Computing. R [computer program]. Version 4.1.3. Vienna, Austria: 2022."},{"issue":"6","key":"924_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1208\/s12248-014-9652-1","volume":"16","author":"G Yu","year":"2014","unstructured":"Yu G, Zheng QS, Li GF. Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective. AAPS J. 2014;16(6):1162\u20136. https:\/\/doi.org\/10.1208\/s12248-014-9652-1.","journal-title":"AAPS J"},{"key":"924_CR18","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/s41598-023-29798-0","volume":"13","author":"S Khalid","year":"2023","unstructured":"Khalid S, Rasool MF, Masood I, Imran I, Saeed H, Ahmad T, et al. Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. Sci Rep. 2023;13:2697. https:\/\/doi.org\/10.1038\/s41598-023-29798-0.","journal-title":"Sci Rep"},{"issue":"4","key":"924_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.xphs.2021.02.001","volume":"110","author":"J Zhou","year":"2021","unstructured":"Zhou J, You X, Ke M, Ye L, Wu W, Huang P, et al. Dosage adjustment for ceftazidime in pediatric patients with renal impairment using physiologically based pharmacokinetic modeling. J Pharm Sci. 2021;110(4):1853\u201362. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.001.","journal-title":"J Pharm Sci"},{"issue":"2","key":"924_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.xphs.2021.10.026","volume":"111","author":"C Ke","year":"2022","unstructured":"Ke C, You X, Lin C, Chen J, Guo G, Wu W, et al. Development of physiologically based pharmacokinetic model for pregabalin to predict the pharmacokinetics in pediatric patients with renal impairment and adjust dosage regimens: PBPK model of pregabalin in pediatric patients with renal impairment. J Pharm Sci. 2022;111(2):542\u201351. https:\/\/doi.org\/10.1016\/j.xphs.2021.10.026.","journal-title":"J Pharm Sci"},{"issue":"3","key":"924_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF03189651","volume":"9","author":"F Keller","year":"1984","unstructured":"Keller F, Maiga M, Neumayer HH, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet. 1984;9(3):275\u201382. https:\/\/doi.org\/10.1007\/BF03189651.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"924_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.07.002.","journal-title":"Pediatr Neurol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00924-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00924-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00924-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:49:06Z","timestamp":1738824546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00924-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00924-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"16 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was sponsored by Acadia Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mona Darwish, Rene Nunez, James M. Youakim, and Di An are employees of and hold stock in Acadia Pharmaceuticals Inc. Kathie M. Bishop is a consultant for Acadia Pharmaceuticals Inc., and former employee. Inger Darling and Viera Lukacova are employees of and hold stock in Simulations Plus, Inc. Thomas C. Marbury is an employee and equity owner of Orlando Clinical Research Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The phase 1 clinical study was approved by an Institutional Review Board and was performed in accordance with Health Insurance Portability and Accountability Act regulations, Food and Drug Administration Good Clinical Practice Regulations, and International Council for Harmonisation Good Clinical Practice Guidelines. All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All study participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available due to data confidentiality but are available from the corresponding author on reasonable request providing a confidentiality agreement is signed.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualisation: MD, JMY, and KMB; Methodology: MD, RN, JMY, DA, ID, VL, and KMB; Data curation, formal analysis, investigation, visualisation: MD, TCM, RN, DA, ID, and VL; Writing (original draft\/previous versions\/approval): MD, TCM, RN, JMY, DA, ID, VL, and KMB.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}